When does GenSight report earnings and why does it matter for SIGHT.PA stock?

GenSight reports after markets on **21 Jan 2026**. The print matters because clinical updates and cash commentary can change investor sentiment and move SIGHT.PA stock quickly.

What is Meyka AI's short-term forecast for SIGHT.PA stock?

Meyka AI's model projects a **monthly target of €0.13**, versus current **EUR 0.0883**, implying about **+47.26%** upside. Forecasts are model-based and not guarantees.

What are the main risks to SIGHT.PA stock around earnings?

Key risks are negative cash flow, trial setbacks, funding need, and potential dilution. Any weak guidance could push SIGHT.PA stock notably lower after the release.

What technical signals should traders watch for SIGHT.PA stock?

Watch **RSI 45.88**, ADX **46.89**, and volume spikes. Tight ranges can break sharply on news, so monitor real-time liquidity before trading SIGHT.PA stock.

EU Stocks

GenSight SIGHT.PA (EURONEXT) pre-market Jan 16 2026: Earnings Jan 21 test

ByDanny Kontos January 16, 2026January 16, 2026

SIGHT.PA stock trades at €0.09 in pre-market on 16 Jan 2026 ahead of an earnings release on 21 Jan 2026. We flag the result as a short-term catalyst for shares of GenSight Biologics S.A. (EURONEXT). The company is a clinical-stage biotech and investors will watch cash runway, trial updates for LUMEVOQ and GS030, and any guidance. Volume and volatility are already higher than average, so the print could move price sharply.